STAT Plus: Engineering a better immunotherapy to outwit cancer — and launch a biotech
A. WALKER, L. SHARP & J. PRYDE/WELLCOME
Tweaking an immune protein called interleukin-18 can overcome tumors that lure it into binding with a decoy receptor protein, new research in mice shows.
.png)
No hay comentarios:
Publicar un comentario